Literature DB >> 12707786

Expression of hepatocyte growth factor and c-Met in the anterior horn cells of the spinal cord in the patients with amyotrophic lateral sclerosis (ALS): immunohistochemical studies on sporadic ALS and familial ALS with superoxide dismutase 1 gene mutation.

Shinsuke Kato1, Hiroshi Funakoshi, Toshikazu Nakamura, Masako Kato, Imaharu Nakano, Asao Hirano, Eisaku Ohama.   

Abstract

To clarify the trophic mechanism of residual anterior horn cells affected by sporadic amyotrophic lateral sclerosis (SALS) and familial ALS (FALS) with superoxide dismutase 1 (SOD1) mutations, we investigated the immunohistochemical expression of hepatocyte growth factor (HGF), a novel neurotrophic factor, and its receptor, c-Met. In normal subjects, immunoreactivity to both anti-HGF and anti-c-Met antibodies was observed in almost all anterior horn cells, whereas no significant immunoreactivity was observed in astrocytes and oligodendrocytes. Histologically, the number of spinal anterior horn cells in ALS patients decreased along with disease progression. Immunohistochemically, the number of neurons negative for HGF and c-Met increased with ALS disease progression. However, throughout the course of the disease, certain residual anterior horn cells co-expressed both HGF and c-Met with the same, or even stronger intensity in comparison with those of normal subjects, irrespective of the reduction in the number of immunopositive cells. Western blot analysis revealed that c-Met was induced in the spinal cord of a patient with SALS after a clinical course of 2.5 years, whereas the level decreased in a SALS patient after a clinical course of 11 years 5 months. These results suggest that the autocrine and/or paracrine trophic support of the HGF-c-Met system contributes to the attenuation of the degeneration of residual anterior horn cells in ALS, while disruption of the neuronal HGF-c-Met system at an advanced disease stage accelerates cellular degeneration and/or the process of cell death. In SOD1-mutated FALS patients, Lewy body-like hyaline inclusions (LBHIs) in some residual anterior horn cells exhibited co-aggregation of both HGF and c-Met, although the cytoplasmic staining intensity for HGF and c-Met in the LBHI-bearing neurons was either weak or negative. Such sequestration of HGF and c-Met in LBHIs may suggest partial disruption of the HGF-c-Met system, thereby contributing to the acceleration of neuronal degeneration in FALS patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12707786     DOI: 10.1007/s00401-003-0708-z

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  9 in total

Review 1.  Motor neuron trophic factors: therapeutic use in ALS?

Authors:  Thomas W Gould; Ronald W Oppenheim
Journal:  Brain Res Rev       Date:  2010-10-21

2.  Pleural mesothelioma instigates tumor-associated fibroblasts to promote progression via a malignant cytokine network.

Authors:  Qi Li; Wei Wang; Tadaaki Yamada; Kunio Matsumoto; Katsuya Sakai; Yoshimi Bando; Hisanori Uehara; Yasuhiko Nishioka; Saburo Sone; Shotaro Iwakiri; Kazumi Itoi; Teruhiro Utsugi; Kazuo Yasumoto; Seiji Yano
Journal:  Am J Pathol       Date:  2011-07-18       Impact factor: 4.307

3.  Effect of FK506 on expression of hepatocyte growth factor in murine spinal cord following peripheral nerve injury.

Authors:  Feng Pan; Anmin Chen; Fengjing Guo; Chenliang Zhu; Fenghua Tao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-05-15

4.  The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system.

Authors:  Caroline C Benoist; Leen H Kawas; Mingyan Zhu; Katherine A Tyson; Lori Stillmaker; Suzanne M Appleyard; John W Wright; Gary A Wayman; Joseph W Harding
Journal:  J Pharmacol Exp Ther       Date:  2014-09-03       Impact factor: 4.030

5.  Intrathecal delivery of recombinant AAV1 encoding hepatocyte growth factor improves motor functions and protects neuromuscular system in the nerve crush and SOD1-G93A transgenic mouse models.

Authors:  Sang Hwan Lee; Subin Kim; Nayeon Lee; Junghun Lee; Seung Shin Yu; Jin Hong Kim; Sunyoung Kim
Journal:  Acta Neuropathol Commun       Date:  2019-06-12       Impact factor: 7.801

6.  Current and emerging treatments for amyotrophic lateral sclerosis.

Authors:  Stefano Zoccolella; Andrea Santamato; Paolo Lamberti
Journal:  Neuropsychiatr Dis Treat       Date:  2009-11-16       Impact factor: 2.570

7.  Beyond Parkinson disease: amyotrophic lateral sclerosis and the axon guidance pathway.

Authors:  Timothy G Lesnick; Eric J Sorenson; J Eric Ahlskog; John R Henley; Lina Shehadeh; Spiridon Papapetropoulos; Demetrius M Maraganore
Journal:  PLoS One       Date:  2008-01-16       Impact factor: 3.240

8.  TDP-43 loss of function inhibits endosomal trafficking and alters trophic signaling in neurons.

Authors:  Benjamin M Schwenk; Hannelore Hartmann; Alperen Serdaroglu; Martin H Schludi; Daniel Hornburg; Felix Meissner; Denise Orozco; Alessio Colombo; Sabina Tahirovic; Meike Michaelsen; Franziska Schreiber; Simone Haupt; Michael Peitz; Oliver Brüstle; Clemens Küpper; Thomas Klopstock; Markus Otto; Albert C Ludolph; Thomas Arzberger; Peer-Hendrik Kuhn; Dieter Edbauer
Journal:  EMBO J       Date:  2016-09-12       Impact factor: 11.598

9.  A Novel HGF/SF Receptor (MET) Agonist Transiently Delays the Disease Progression in an Amyotrophic Lateral Sclerosis Mouse Model by Promoting Neuronal Survival and Dampening the Immune Dysregulation.

Authors:  Antonio Vallarola; Massimo Tortarolo; Roberta De Gioia; Luisa Iamele; Hugo de Jonge; Giovanni de Nola; Enrica Bovio; Laura Pasetto; Valentina Bonetto; Mattia Freschi; Caterina Bendotti; Ermanno Gherardi
Journal:  Int J Mol Sci       Date:  2020-11-12       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.